Torna al Dataset
Documento #539
Processato
Contenuto Testuale
Technology evaluation: BL22, NCI. BL22 (RFB4(dsFv)-PE38) is a recombinant Pseudomonas exotoxin-based immunotoxin under development by the National Cancer Institute for the treatment of B-cell malignancies. It is composed of the disulfide-stabilized Fv portion of the anti-CD22 antibody RFB4 genetically fused to a truncated form of Pseudomonas exotoxin A. It has entered phase I trials for the treatment of B-cell lymphoma.
Vettore Embedding
[-0.07452031, -0.026191028, 0.00080598274, -0.035388082, 0.05449404, ... ]
- Dimensioni 768 dim
- Creato il 31/03/2026 15:19
- Model